Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1

被引:45
|
作者
Ataga, Kenneth I. [1 ,2 ]
Brittain, Julia E. [2 ,3 ]
Moore, Dominic [4 ]
Jones, Susan K. [1 ,2 ]
Hulkower, Ben [2 ]
Strayhorn, Dell [1 ,2 ]
Adam, Soheir [1 ,2 ]
Redding-Lallinger, Rupa [2 ,5 ]
Nachman, Patrick [6 ]
Orringer, Eugene P. [1 ,2 ]
机构
[1] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Comprehens Sickle Cell Program, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[5] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA
[6] Univ N Carolina, Div Nephrol & Hypertens, Chapel Hill, NC 27599 USA
关键词
hemophilia A; mutations; structure-function; factor VIII; GROWTH-FACTOR RECEPTOR; 3RD NATIONAL-HEALTH; RISK-FACTORS; RENAL-FUNCTION; CHILDREN; MICROALBUMINURIA; ADULTS; PREVALENCE; FAILURE; ANEMIA;
D O I
10.1111/j.1600-0609.2010.01471.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Hemophilia A (HA) is a common X-linked recessive bleeding disease caused by mutations in FVIII gene. The identification of mutation in HA subjects can lead to more accurate diagnosis and contribute to the genetic counseling/prenatal diagnosis. Objectives: Our objective is to identify the FVIII defects in 148 unrelated Chinese HA subjects and to analyze the potential consequence of novel mutations. Methods: FVIII: C was assayed using one-stage method, and FVIII inhibitor was tested using Bethesda method. Intron 22 and 1 inversions were identified by PCR technique. Non-inversion mutations of FVIII gene were identified by direct sequencing. Novel mutations were further analyzed based on a B-domain deleted FVIII crystallographic structure and bioinformatics tools. Results: The intron 22 and 1 inversions affected 57 and three severe subjects, respectively. Sixty-seven different mutations were identified in non-inversion subjects including 35 novel mutations that were not reported previously. Novel mutations include five nonsense mutations, 15 missense mutations, three insertions, eight small deletions, two splice site mutations and two partial gene deletions. The potential deleterious effects of these novel missense mutations include disruption of the protein core, impairment of inter-domain interaction and FVIII binding with other proteins. Conclusion: Similar to other races, intron 22 and one inversions are also recurrent mutation in severe HA subjects monitored in our centre. Sixty-seven mutations (52% novel reported) among 88 non-inversion subjects represent the high degree of heterogeneity of FVIII gene mutations causing HA. Characteristic of HA FVIII gene mutations extend our insight into structure-function relationship of the FVIII molecule.
引用
收藏
页码:257 / 263
页数:7
相关论文
共 50 条
  • [31] Elevated serum levels of soluble fms-like tyrosine kinase-1 in hemodialysis patients:: A possible role as an inhibitor of neovascularization
    Ebihara, Itaru
    Hirayama, Kouichi
    Seki, Masanori
    Nagai, Miho
    Ogawa, Yujiro
    Fujita, Shogo
    Nakamura, Hideko
    Kobayashi, Masaki
    Usui, Joichi
    Yamagata, Kunihiro
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 186 - 187
  • [32] Relationship between urinary albumin and serum soluble fms-like tyrosine kinase 1 (sFlt-1) in normal pregnancy
    Yoshimatsu, Jun
    Matsumoto, Harunobu
    Goto, Kiyomi
    Shimano, Masako
    Narahara, Hisashi
    Miyakawa, Isao
    EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2006, 128 (1-2): : 204 - 208
  • [33] Soluble Fms-like tyrosine kinase-1 (sFlt-1) is associated with subclinical and clinical atherosclerotic cardiovascular disease: The Dallas Heart Study
    Mauricio, Rina
    Singh, Kavisha
    Sanghavi, Monika
    Ayers, Colby R.
    Rohatgi, Anand
    Vongpatanasin, Wanpen
    de Lemos, James A.
    Khera, Amit
    ATHEROSCLEROSIS, 2022, 346 : 46 - 52
  • [34] SOLUBLE FMS-LIKE TYROSINE KINASE-1 (SFLT-1) IS ASSOCIATED WITH SUBCLINICAL AND CLINICAL ASCVD: THE DALLAS HEART STUDY
    Mauricio, Rina
    Singh, Kavisha
    Sanghavi, Monika
    Ayers, Colby
    Rohatgi, Anand
    Vongpatanasin, Wanpen
    de Lemos, James
    Khera, Amit
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1919 - 1919
  • [35] Regulation of soluble fms-like tyrosine kinase-1 production in response to placental ischemia/hypoxia: role of angiotensin II
    Murphy, Sydney R.
    Cockrell, Kathy
    PHYSIOLOGICAL REPORTS, 2015, 3 (02):
  • [36] The Soluble Fms-like Tyrosine Kinase-1 Contributes to Structural and Functional Changes in Endothelial Cells in Chronic Kidney Disease
    Schulz, Annika
    Drost, Carolin Christina
    Hesse, Bettina
    Beul, Katrin
    Brand, Marcus
    Di Marco, Giovana Seno
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [37] The involvement of soluble fms-like tyrosine kinase-1 in the transition from acute kidney injury to chronic kidney disease
    Hikari, Tasaki
    Tsushima, Hideo
    Eriguchi, Masahiro
    Uemura, Takayuki
    Tamaki, Hiroyuki
    Nishimoto, Masatoshi
    Kosugi, Takaaki
    Samejima, Ken-Ichi
    Tsuruya, Kazuhiko
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [38] Increased expression levels of soluble fms-like tyrosine kinase-1 inhibits the development of the nervous system
    Xu, Xia
    Liao, Tingting
    Jiang, Rumeng
    Ye, Xu
    Yan, Jianying
    NEUROENDOCRINOLOGY, 2023, 113 (07) : 692 - 704
  • [39] Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease
    Sinning, Christoph
    Schnabel, Renate B.
    Zeller, Tanja
    Seiffert, Moritz
    Rupprecht, Hans J.
    Lackner, Karl J.
    Blankenberg, Stefan
    Bickel, Christoph
    Westermann, Dirk
    BIOMARKERS IN MEDICINE, 2016, 10 (01) : 95 - 106
  • [40] The involvement of soluble fms-like tyrosine kinase-1 in the transition from acute kidney injury to chronic kidney disease
    Hikari, Tasaki
    Tsushima, Hideo
    Eriguchi, Masahiro
    Uemura, Takayuki
    Tamaki, Hiroyuki
    Nishimoto, Masatoshi
    Kosugi, Takaaki
    Samejima, Ken-Ichi
    Tsuruya, Kazuhiko
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I356 - I357